Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
Androgen receptor stops tumor growth in the most common form of breast cancer

Androgen receptor stops tumor growth in the most common form of breast cancer

byThe Endocrine SocietyCredit: CC0 Public DomainResearchers say they have found a viable new therapeutic strategy for estrogen receptor-positive (ER+) breast cancer, even cancers that are resist

Androgen receptor stops tumor growth in the most common form of breast cancer

byThe Endocrine SocietyCredit: CC0 Public DomainResearchers say they have found a viable new therapeutic strategy for estrogen receptor-positive (ER+) breast cancer, even cancers that are resist
Women's wellness: Sexual health after cancer treatment

Women's wellness: Sexual health after cancer treatment

by From Mayo Clinic News NetworkCredit: CC0 Public DomainFollowing a cancer diagnosis, patients often ask many questions about their treatment and possible side effects. One area that is often overloo

Women's wellness: Sexual health after cancer treatment

by From Mayo Clinic News NetworkCredit: CC0 Public DomainFollowing a cancer diagnosis, patients often ask many questions about their treatment and possible side effects. One area that is often overloo
New study suggests weight gain may reduce breast cancer risk

New study suggests weight gain may reduce breast cancer risk

by Crystal VillarrealCredit: CC0 Public DomainA recent study published in theInternational Journal of Cancer, has found that women who gain weight from early adulthood are at a reduced risk of d

New study suggests weight gain may reduce breast cancer risk

by Crystal VillarrealCredit: CC0 Public DomainA recent study published in theInternational Journal of Cancer, has found that women who gain weight from early adulthood are at a reduced risk of d
Fiber consumption linked to lower breast cancer risk

Fiber consumption linked to lower breast cancer risk

byWileyMammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainConsuming a diet high in fiber was linked with a reduced incidence of breast cancer in an

Fiber consumption linked to lower breast cancer risk

byWileyMammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainConsuming a diet high in fiber was linked with a reduced incidence of breast cancer in an
HER2-targeted therapy trastuzumab deruxtecan shows early promise in patients with non-breast and non-gastric cancers

HER2-targeted therapy trastuzumab deruxtecan shows early promise in patients with non-breast and non-gastric cancers

byAmerican Association for Cancer ResearchA HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric

HER2-targeted therapy trastuzumab deruxtecan shows early promise in patients with non-breast and non-gastric cancers

byAmerican Association for Cancer ResearchA HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric
In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

byNational Cancer InstituteFindings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the t

In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

byNational Cancer InstituteFindings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the t
Breast density, microcalcifications, and masses may be heritable traits

Breast density, microcalcifications, and masses may be heritable traits

byAmerican Association for Cancer ResearchAn analysis of a large Swedish cohort revealed that breast density, microcalcifications, and masses are heritable features, and that breast density and

Breast density, microcalcifications, and masses may be heritable traits

byAmerican Association for Cancer ResearchAn analysis of a large Swedish cohort revealed that breast density, microcalcifications, and masses are heritable features, and that breast density and
FDA approves first ever treatment for neurofibromatosis

FDA approves first ever treatment for neurofibromatosis

by Children's Tumor FoundationThe U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in

FDA approves first ever treatment for neurofibromatosis

by Children's Tumor FoundationThe U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in
Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction

byThe Endocrine SocietyThyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that w

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction

byThe Endocrine SocietyThyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that w
The importance of family caregivers on a cancer journey

The importance of family caregivers on a cancer journey

byUniversity of Hawaii at ManoaA University of Hawai'i Cancer Center study found the presence of a family caregiver created positive perceptions of care coordination from cancer patients. Ca

The importance of family caregivers on a cancer journey

byUniversity of Hawaii at ManoaA University of Hawai'i Cancer Center study found the presence of a family caregiver created positive perceptions of care coordination from cancer patients. Ca
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...